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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
Introduction: Painful bladder syndrome/interstitial cystitis (PBS/IC) pathogenesis is not 
fully known, but evidence shows that glycosaminoglycans (GAG) of bladder urothelium 
can participate in its genesis. The loss of these compounds facilitates the contact of urine 
compounds with deeper portions of bladder wall triggering an inflammatory process. We 
investigated GAG in urine and tissue of PBS/IC and pure stress urinary incontinence (SUI) 
patients to better understand its metabolism.
Materials and Methods: Tissue and urine of 11 patients with PBS/IC according to NIDDK 
criteria were compared to 11 SUI patients. Tissue samples were analyzed by histological, 
immunohistochemistry and immunofluorescence methods. Statistical analysis were per-
formed using t Student test and Anova, considering significant when p < 0.05.
Results: PBS/IC patients had lower concentration of GAG in urine when compared to SUI 
(respectively 0.45 ± 0.11 x 0.62 ± 0.13 mg/mg creatinine, p < 0.05). However, there was no 
reduction of the content of GAG in the urothelium of both groups. Immunofluorescence 
showed that PBS/IC patients had a stronger staining of TGF-beta, decorin (a proteoglycan 
of chondroitin/dermatan sulfate), fibronectin and hyaluronic acid.
Conclusion: the results suggest that GAG may be related to the ongoing process of in-
flammation and remodeling of the dysfunctional urothelium that is present in the PBS/IC.
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INTRODUCTION
Painful bladder syndrome/interstitial cysti-
tis (PBS/IC) is a chronic syndrome that affects the 
lower urinary tract and which diagnosis is based 
on urinary symptoms and chronic pelvic pain or 
discomfort related to the bladder (1). Its aetiopa-
thology is not fully known, but it is believed that 
the glycosaminoglycans (GAGs) and proteoglycans 
(PGs) that line the bladder urothelium can active-
ly participate in its genesis. They potentially help 
to prevent infections, stone formation, and tissue 
damage related to radiation carcinogenesis and in-
terstitial cystitis. The biological activity of this layer 
is generated by the anionic charge of the polysac-
charides forming the GAG. They are highly hydro-
philic and are adhered to the surface of transitio-
nal cell bladder. That avidity for water molecules 
creates a barrier that prevents migration of solutes 
from urine through epithelium (2,3). Their capacity 
to prevent part of the urinary solutes to reach the 
interstitium has been demonstrated in studies that 
found increased urea and potassium absorption by 
bladder wall when the GAG layer is damaged.
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Urine and tissue levels of GAG have been 
studied in PBS/IC and in animal models but their 
results are not uniform (2,4-18). Such variation sug-
gests that there is no complete understanding of how 
and why GAG is produced and degraded in PBS/IC, 
if GAG expression is the cause or the reaction for 
PBS/IC. Or both cause and reaction. The mechanisms 
of changes in GAG levels that can occur during the 
course of the syndrome are not precisely described 
although some have correlated disease severity to 
symptoms (4). We investigated GAG behavior in an 
attempt to understand its metabolism and the che-
mical reactions related to the expression of those po-
lisaccharides in tissue and urine.
MATERIAL AND METHODS
 Female patients with confirmed diagnosis 
of PBS/IC (n = 11) according to the NIDDK criteria 
except for glomerulations were subjected to clini-
cal questionnaire assessing age, date of onset of 
symptoms, coexisting diseases, severity of symp-
toms, type of previous treatment and quality of 
life index. They underwent cystoscopy for urine 
collection followed by bladder biopsy. In the same 
procedure bladder hydrodistention was done for 3 
minutes and 80cmH20 pressure (19). Mean age was 
48 (26-73) years.
 The control group (n = 11) was composed 
of female patients with pure stress urinary incon-
tinence (SUI) that also underwent bladder biop-
sies at the time of cystoscopy as a part of surgi-
cal correction of the underlying disease. Again a 
new sample of urine was collected at the time of 
the surgery and bladder biopsy was taken. These 
patients also had previous negative urinary cul-
ture and an urodynamic study realized 3 months 
earlier in order to exclude eventual non-inhibited 
detrusor contraction. This group was chosen as 
the control group because a bladder cold biopsy 
would add little risk to them, as cystoscopy was 
mandatory in their surgical treatment. Mean age 
was 64 (50-79) years.
 The study was approved by the ethics 
committees and a consent form was signed by 
participants.
 The tissue samples were referred to the 
following analysis: histological, immunohisto-
chemistry and immunofluorescence, and RNA ex-
pression by real time PCR.
Extraction of Tissue Glycosaminoglycans
Tissue samples from six patients with in-
terstitial cystitis and 7 controls (SUI) were proces-
sed and analyzed biochemically for the content 
of sulfated GAG, as previously described (20-22). 
Briefly, the bladder tissue samples were shred-
ded into 10 volumes of acetone to remove water 
and lipids. The ketonic powder obtained was then 
subjected to proteolysis with the enzyme maxa-
tase 4mg/ml (Biocon Industrial of Brazil, Rio de 
Janeiro, Brazil) in Tris-HCL50mM, NaCl1M, pH 
8.0, “overnight”. Peptides and nucleic acids were 
precipitated with trichloroacetic acid 90%, and the 
GAG precipitated from the supernatant by addition 
of methanol.  After incubation at -20ºC, 18 hours, 
the precipitate (containing GAGs) was dried and 
resuspended in distilled water (1mL for each mg 
of dry tissue). The identification of the different 
GAG obtained by the procedure above was done by 
agarose gel electrophoresis in 1.3 diaminopropane 
acetate buffer 0.05 M, pH 9.0 (PDA). Five mL of 
each sample as well as 5μL of a mixture of stan-
dard GAG (containing 1mg/mL of chondroitin sul-
fate, dermatan sulfate and heparan sulfate, all of 
Seikagaku Kogyo Co., Tokyo, Japan) were applied 
to the same gel and subjected to electrophoresis, 
100V, one hour. The starting point of electropho-
resis corresponds to the negative pole as a func-
tion of the negative charge of GAG they migrate 
toward the positive pole. Thus, this system can 
discriminate, in order of decreasing electrophore-
tic mobility, three major GAG: chondroitin sulfate 
(CS), the dermatan sulfate (DS) and heparan sulfate 
(HS), respectively. Finally, the GAG were precipi-
tated in the gel by the addition of cetyltrimethyl 
ammonium bromide (CETAVLON, Sigma-Aldrich, 
St. Louis, MO) 0.1% for a minimum of two hours 
at room temperature. After drying under heat and 
ventilation, the gel was stained with toluidine blue 
solution 0.1% acetic acid 1% and 50% ethanol for 
about 15 minutes. The excess dye was removed 
with a solution of 1% acetic acid in 50% ethanol. 
Quantification of GAG present in different samples 
was performed by optical densitometry equipment 
in A595nm QuickScan (Helena Laboratories, Seiko, 
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Japan) and compared to the existing content of the 
standard mix. The values were expressed as mg/mg 
of dry powder.
Extraction and quantification of sulfated GAGs 
and hyaluronic acid in the urine
 For analysis of sulfated GAG, 8mL of each 
urine were concentrated and washed twice with 
distilled water (8mL) in tubes of Amicon Ultra 
concentration 3kDa (Millipore Corporation, Car-
rigtwohill, Ireland) to a final volume of 20mL. 
Five mL of the solution were subjected to elec-
trophoresis as described above, and the GAG pre-
sent in the sample quantified by comparison with 
a standard mix of GAG (containing 1mg/mL of 
chondroitin sulfate, dermatan sulfate and hepa-
ran sulfate, all of Seikagaku Kogyo Co, Tokyo, 
Japan). The content of GAG present in different 
samples was expressed as mg/mg creatinine. The 
analysis of the HA method was performed as pre-
viously described (23,24). Briefly, 100mL/well of 
each urine (diluted 1:2 in assay buffer Tris-HCl0, 
05M, pH 7.75 + 1% BSA) and the same amount 
of a standard curve (0-1000ng/mL) from human 
umbilical cord HA (Sigma-Aldrich, St. Louis, MO) 
were applied in triplicate in ELISA plates (Perkin-
-Elmer Life Sciences-WallacOy, Turku, Finland) 
pre coated with an HA-binding protein extracted 
from bovine nasal cartilage (21). After incubation 
at 4ºC, 12 hours, the plates were washed six times 
with wash buffer (Tris-HCl0, 05M, pH 7.75) follo-
wed by the addition of HA binding protein labe-
led with biotin (1mg/mL) diluted in assay buffer. 
The plates were then shaken at room temperature 
for 2 hours and washed 12 times with the wash 
buffer to remove protein not complexed to the 
biotinylated HA retained on board. Finally, the 
presence of biotin on the plate was determined by 
adding 100mL/well of streptavidin labeled with 
europium (Perkin-Elmer Life Sciences-WallacOy, 
Turku, Finland) diluted 1:10,000 in assay buffer, 
30 minutes. To measure the fluorescence emitted 
by europium, 200mL of a solution Enhancement 
(Perkin-Elmer Life Sciences-WallacOy, Turku, 
Finland) were added to each well and read on 
equipment Victor 2 (Perkin-Elmer Life Sciences-
-WallacOy, Turku, Finland). HA values were ex-
pressed in ng/mg of creatinine.
Immunofluorescence of tissue
 The tissue samples of patients with PBS/IC 
(n = 6) and control patients with SUI (n = 4) were 
washed in PBS and immediately fixed in 4% para-
formaldehyde solution for 2 hours at room tempera-
ture. Then the fragments were embedded in freezing 
medium for fluorescence Tissue freezing medium - 
Tissue Tek (SakuraFinetek USA, Inc., Torrance, CA, 
USA) and frozen on dry ice and isopentane, and 
kept in a freezer at -70ºC, which were placed on 
silanized slides. The following cuts were made in 
a cryostat (Leica, Wetzlar, Germany) with a thick-
ness of about 5mm. For immunofluorescence reac-
tions the sections were washed five times with PBS 
and one time with PBS containing 0.1M glycine At 
this stage three antibody combinations were made 
in separate slides for analysis: 1) anti-CD44 (Santa 
Cruz Bioechnology Inc., CA, USA) vs. probe of bio-
tinylated HA binding protein (prepared in our labo-
ratory according to Martins et al., 2003); 2) anti-
decorim (Seikagaku, Japan) vs. anti-TGF-β (Santa 
Cruz Bioechnology Inc., CA, USA); 3) anti-SINDEC 
(Bioechnology Inc. Santa Cruz, CA, USA) vs. anti-
-fibronectin (Bioechnology Inc. Santa Cruz, CA, 
USA). The slides were incubated with the antibod-
ies mentioned above and also with the acid-binding 
protein, for 2 hours at room temperature. At the end 
of incubation, the slides were washed 3 times in 
PBS, and now incubated with secondary antibody 
or streptavidin conjugated with fluorescent marker 
Alexa FluorTM 488 or 594 or 546 or 630 or 430 (the 
number corresponds to the wavelength of excita-
tion of the fluorophore conjugated) diluted 1:300 
in PBS. After 30 min. of incubation, the slides were 
washed five times in PBS and nuclei were marked 
with DAPI (4’6-diamidino-2-phenylindole, dihidro-
cloride - marking in blue) 1:10,000 in PBS contain-
ing 0.01% saponin (detergent that permeates the cell 
membrane) for 30 min. Next, the slides were washed 
five times in PBS, washed again in ultrapure water 
and finally mounted with coverslips in histological 
Fluormont G (Electron Microscopy Sciences, Hat-
field, PA, USA). The slides were observed and ana-
lyzed with a fluorescence microscope (Nikon Eclipse, 
TE300 and TE800, Tokyo, Japan) and confocal mi-
croscope (LSM500 meta - Carl Zeiss, Germany). The 
controls for the immunostaining experiments were 
performed omitting the primary antibody.
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RESULTS
 Table-1 summarizes the demographics of 
the patients.
 Although the average concentration of 
GAG in tissue was higher in patients with PBS/
IC (3.3mg/mg dry tissue, range: 0.58 to 7.08) than 
in the control group (2.7mg/mg dry tissue, ran-
ge: 0.15 to 5.3), this difference was not statisti-
cally significant (p = 0.62) (Figure-1). Chondroitin 
sulfate (CS) and dermatan sulfate (DS) were com-
pared to heparin sulfate (HS): CS + DS were the 
main component in the urothelium (mean CS + 
DS: PBS/IC 74.3%, control 78%; mean HS: PBS/IC 
25.7%; control 22%).
 In urine we found a statistically signi-
ficant decrease (p < 0.05) of GAG in the PBS/IC 
group (0.45 ± 0.11mg/mg creatinine) compared to 
Table 1 - Demographics of IC/PBS and SUI patients.
Pacient Age (Year) Symptoms Urinary culture at surgery
IC/PBS 1 27 Vesical pain, nicturia Negative
IC/PBS 2 40 Vesical pain, nicturia Negative
IC/PBS 3 53 Supra pubic pain, nicturia Negative
IC/PBS 4* 64 Nicturia E.coli
IC/PBS 5 65 Vesical pain, nicturia, anal pain, dispareunia Negative
IC/PBS 6 73 Vesical pain, nicturia, frequency Negative
IC/PBS 7 43 Vesical pain, nicturia, dispareunia Negative
IC/PBS 8 27 Vesical pain, nicturia Negative
IC/PBS 9 57 Supra pubic pain, nicturia, dispareunia, frequency Negative
IC/PBS 10 26 Supra pubic pain, nicturia, dispareunia, frequency Negative
IC/PBS 11 48 Supra pubic pain, nicturia, dispareunia, frequency Negative
SUI 1 68 Stress urinary incontinence Negative
SUI 2 53 Stress urinary incontinence Negative
SUI 3 71 Stress urinary incontinence Negative
SUI 4 64 Stress urinary incontinence Negative
SUI 5 61 Stress urinary incontinence Negative
SUI 6 59 Stress urinary incontinence Negative
SUI 7 64 Stress urinary incontinence Negative
SUI 8 50 Stress urinary incontinence Negative
SUI 9 79 Stress urinary incontinence Negative
SUI 10 66 Stress urinary incontinence Negative
SUI 11 54 Stress urinary incontinence Negative
* This patient was excluded because of UTI.
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the control group (0.62 ± 0.13mg/mg creatinine) 
(Figure-2). The percentage of GAG found in the 
urine of PBS/IC and controls was similar.
 Although the average concentration of HA 
was lower in the PBS/IC group (1.71 ± 2.06ng/mg 
creatinine) compared to the control group (2.46 
± 2.07ng/mg creatinine), this difference was not 
significant (p = 0.48).
 The immunofluorescence study revealed 
an intense labeling for HA without a correspon-
ding increase in the expression of its receptor, 
CD44 (Figure-3). The expression of TGF-β and de-
corim was marked with greater intensity in two 
patients compared to controls. There was also an 
intense labeling for fibronectin in patients com-
pared to controls. Syndecan-4 had a significant 
decrease in expression.
DISCUSSION
 In the present study we were able to show 
that urinary levels of GAG are lower in PBS/IC 
patients when compared to controls but the rela-
tive proportion of each GAG is the same in both 
groups. On the other hand, tissue concentration of 
GAG was similar. HA in urine was similar in both 
groups but in immunofluorescence HA labeling 
was more intense in PBS/IC patients. The same 
happened for fibronectin, decorin and TGF-β.
 Urinary GAG content in PBS/IC patients 
has been shown to be decreased (25,26), similar 
(27,28) and increased (4,13,18). Our results sho-
wed a significant decrease in urinary excretion of 
sulfated GAG of patients with PBS/IC compared 
to the controls. Moreover, unlike previous studies, 
the technique employed in this study showed that 
the reduction in urinary GAG excretion in patients 
with PBS/IC occurred uniformly, with no predi-
lection for any urinary GAG. Our study was not 
managed to analyze urinary GAG and the activity 
of the disease, such as degree of symptoms, glome-
rulation and histologic findings since they are not 
Figure 1 - Urothelium concentration of sulfated GAG of IC/
BS and control (SUI) patients. Vertical bars represent the 
standard deviations. Statistically significant deviation was 
not found between groups (p = 0.62).
Figure 2 - Urinary concentration of sulfated GAG of IC/
PBS and control (SUI) patients. Vertical bars represent the 
standard deviations. Statistically significant difference was 
found between groups (p < 0.05).
Figure 3 - Immunoflurorescence of hyaluronic acid (HA) and 
its receptor (CD44) in the bladder urothelium. The tissue of 
SIU patients (CTR) and IC/PBS patients (PAT) were labeled 
with anti-HA receptor (green) and a protein biotinylated HA 
binding (red). The nuclei were stained with DAPI (blue). The 
overlap of the markings appears in the right pane (merged). 
Scale bar: 50µm.
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reliable isolated markers today (29). As for the HA, 
although the average urinary concentration was 
lower in the PBS/IC group but there was no signifi-
cant difference when compared to control. Distinct 
methods of extraction could explain such varia-
tion. But it is possible that PBS/IC level of activity 
may influence urinary GAG level. As previously 
stated, correlation between urinary GAG level and 
symptoms has already been described (4,13,18). 
We were not able to make such correlation.
 However, urinary GAG level does not cor-
relate to tissue GAG level. GAG expression in tis-
sue has already been studied and no change in 
the content of GAG in the urothelium of patients 
with PBS/IC was described (8). The present study 
did not found statistically significant difference 
in the concentration of sulfated GAG in the uro-
thelium of PBS/IC patients compared to controls. 
Hurst and Zebrowski (14) found the HS as the 
predominant GAG in the urothelium of patients 
with PBS/IC (55% of total GAG) but in our stu-
dy the major GAG present in those urothelium 
was a combination of CS + DS which accounted 
for about 80% of the total. That proportion was 
not different from that of the controls meaning 
they had a decrease of total GAG in tissue but 
not a predilection for any GAG. Different me-
thods of extraction and analysis of the different 
GAG could justify such differences. Moreover, the 
small size of the fragments availabe for the study 
may have hindered the analysis and the interpre-
tation of these data.
 Growth factors may be also increased in 
patients with PBS/IC (30). We have demonstrated 
by immunofluorescence increased expression of 
TGF-β. Simultaneously the expression of deco-
rin was increased, a proteoglycan composed of 
CS and DS chains involved in the regulation of 
various cellular functions such as proliferation, 
adhesion and migration, which is able to mediate 
the binding of TGF-β with its membrane receptor 
(31). As the action of TGF-β depends on deco-
rin, it makes sense that decorin is increased in a 
scenario of increased TGF-β. We also noticed an 
intense labeling of fibronectin in tissues of PBS/
IC, especially in the deeper layers of tissue. Fi-
bronectin is a glycoprotein with important role 
of scaffold in the extracellular matrix, regulating 
the cellular architecture and matrix components. 
Those higher expressions may represent modifi-
cations in the extracellular in an attempt to re-
covery urothelial damage. But one can not as-
sure they are specific to PBS/IC. Variations are 
described in literature and this topic also remains 
controversial (9,15,16).
 Syndecan is a transmembrane receptor 
that mediates cell adhesion to fibronectin, playing 
a key role in healing. Its lower expression was 
consistent with a previous study from our group 
that observed in animal models loss of expression 
of HS and syndecan on the surface of the uro-
thelium of rats after induction of inflammation 
with DMSO (9). As shown in the study, it may be 
results from desquamation of the dysfunctional 
urothelium.
 Another important step in this study was 
the evaluation of the expression of HA and its 
receptor CD44 in the urothelium by immunostai-
ning.  Hyaluronic acid is a key component of the 
extracellular matrix due to its viscoelastic pro-
perties and its hygroscopic capacity, promoting 
hydration and turgidity. The HA forms a base to 
which other proteoglycans can bind (32). It was 
remarkable that AH showed intense labeling in 
the urothelium of PBS/IC compared to controls, 
while CD44 did not labeled significantly different. 
That could represent a paradox at a glance. The 
CD44 is the major membrane receptor for HA and 
is responsible, among other things, by its binding 
to and internalization into cells where this ele-
ment is digested by lysosomal hyaluronidase and 
the digestion products are reused for new synthe-
sis (33). The combination of intense marking HA 
without a corresponding increase in the marking 
of its receptor may indicate a change of its tur-
nover in the urothelium of PBS/IC ending up this 
compound to be “stored” in the interstitial. That 
pattern may represent a response to inflamma-
tion. In studies of mice lacking the CD44 recep-
tor (knock-out) accumulation of hyaluronic acid 
is seen during bleomycin-induced lung inflam-
matory process. The result is excessive and un-
controlled severity of the inflammatory process 
leading to death of the animal (34).
 Although we found a heterogeneous pat-
tern of immunofluorescence for all patients with 
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PBS/IC, our findings are in agreement with other 
researchers, that analyzed biomarkers by immu-
nohistochemistry in the urothelium of patients 
with cystitis and found distinct patterns of ma-
rking, sometimes with predominance of either one 
of a set of matrix components, but all the profiles 
different from those found in normal urothelium 
(15,16). Whereas the inflammatory involvement 
of the urothelium does not occur uniformly, our 
current results and also those of Hauser et al. (16) 
suggest different profiles of involvement and ex-
pression of various inflammatory components of 
the extracellular matrix and depending on the di-
fferent stages of inflammation and/or remodeling 
that each segment of the bladder is subject. That 
is why a pattern of GAG expression has not been 
achieved. Because those differences, one may 
speculate that they are not PBS/IC specific in-
flammatory process but rather a non-specific re-
action to any aggression. In attempts to recovery, 
modeling of the extracellular matrix takes place 
in a dysfunctional urothelium. As the process is 
going on, distinct expressions may be identified 
and help to understand the phase of the disease.
 The main limitation of this study is the 
small number of patients. Control patients were 
those with urinary incontinence subjected to sur-
gical correction because bladder biopsy would 
add little risk to them. Even in those patients fin-
ding a volunteer was a challenge that would be 
more difficult when looking for healthy controls. 
The same limitation in the number of PBS/IC pa-
tients was found because the necessity of norma-
lizing their selection for research restricts in up 
to 60% of those with clinically PBS/IC (35). There 
may also have had some bias in patient selection 
because our hospital is a tertiary referral for IC/
PBS. Another important issue was the small size 
of bladder biopsies. They were used for all the 
analyses and could not be taken in big bites be-
cause PBS/IC bladders have typically a high de-
gree of inflammation and were done in the same 
procedure of hydrodistention.
CONCLUSIONS
 The alterations in GAG may be related to 
an ongoing process of inflammation and tissue re-
modeling in a dysfunctional urothelum, reflecting 
the pathophysiology of the disease.
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